alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 10.53
                              Note to Exhibit 10.53



         The following Indenture Supplement is substantially identical in all
material respects to five additional Indenture Supplements except as follows:

<TABLE>
<CAPTION>

Owner Participant                                       Date                                    Aircraft (Tail No.)
-----------------                                       ----
<S>                                                     <C>                                     <C>
NCC Charlie Company*                                    September 10, 1998*                     N575ML*
NCC Charlie Company                                     September 10, 1998                      N576ML
General Electric Capital Corporation                    November 10, 1998                       N577ML
General Electric Capital Corporation                    November 10, 1998                       N578ML
Castle Harbour Leasing Inc.                             December 10, 1998                       N579ML                        
NCC Charlie Company                                     January 25, 1999                        N580ML                       
</TABLE>



------------------

*          Filed document
Exhibit 21

List of Subsidiaries



|                                             |  |                             
|-------------------------------------------- |  | ----------------------------
|Subsidiary                                   |  | Jurisdiction of Organization
|MEMC Asia-Pacific Holdings BV                |  | The Netherlands             
|MEMC Electronic Materials France SarL        |  | France                      
|MEMC Electronic Materials, GmbH              |  | Germany                     
|MEMC Electronic Materials Sales, Sdn. Bhd.   |  | Malaysia                    
|MEMC Electronic Materials, Sdn. Bhd.         |  | Malaysia                    
|MEMC Electronic Materials, S.p.A.            |  | Italy                       
|MEMC Electronic Materials (UK) Ltd.          |  | United Kingdom              
|MEMC Enterprise Consulting Shanghai Co. Ltd. |  | China                       
|MEMC Holding B.V.                            |  | The Netherlands             
|MEMC Holdings Corporation                    |  | Delaware                    
|MEMC International Finance SarL              |  | Luxembourg                  
|MEMC International, Inc.                     |  | Delaware                    
|MEMC Ipoh Sdn Bhd.                           |  | Malaysia                    
|MEMC Japan Ltd.                              |  | Japan                       
|MEMC Korea Company                           |  | South Korea                 
|MEMC Kulim Electronic Materials, Sdn. Bhd.   |  | Malaysia                    
|MEMC Luxembourg SarL                         |  | Luxembourg                  
|MEMC Pasadena, Inc.                          |  | Delaware                    
|MEMC Singapore Pte. Ltd.                     |  | Singapore                   
|Taisil Electronic Materials Corporation      |  | Taiwan
<TABLE> <S> <C>

<ARTICLE> UT
<LEGEND>
This schedule contains summary financial information extracted from the Form
10-K for December 31, 1996, and is qualified in its entirety by reference to
such financial statements.
</LEGEND>
<CIK> 0000945979
<NAME> MOBILE ENERGY SERVICES HOLDINGS, INC.
       
<S>                                 <C>
<PERIOD-TYPE>              YEAR
<FISCAL-YEAR-END>                                             DEC-31-1996
<PERIOD-END>                                                  DEC-31-1996
<BOOK-VALUE>                                                  PER-BOOK
<TOTAL-NET-UTILITY-PLANT>                                     354,889
<OTHER-PROPERTY-AND-INVEST>                                   0
<TOTAL-CURRENT-ASSETS>                                        62,488
<TOTAL-DEFERRED-CHARGES>                                      14,188
<OTHER-ASSETS>                                                0
<TOTAL-ASSETS>                                                431,565
<COMMON>                                                      1
<CAPITAL-SURPLUS-PAID-IN>                                     30,623
<RETAINED-EARNINGS>                                          (17)
<TOTAL-COMMON-STOCKHOLDERS-EQ>                                30,607
<PREFERRED-MANDATORY>                                         0
<PREFERRED>                                                   0
<LONG-TERM-DEBT-NET>                                          303,811
<SHORT-TERM-NOTES>                                            0
<LONG-TERM-NOTES-PAYABLE>                                     0
<COMMERCIAL-PAPER-OBLIGATIONS>                                0
<LONG-TERM-DEBT-CURRENT-PORT>                                (7,350)
<PREFERRED-STOCK-CURRENT>                                     0
<CAPITAL-LEASE-OBLIGATIONS>                                   0
<LEASES-CURRENT>                                              0
<OTHER-ITEMS-CAPITAL-AND-LIAB>                                97,147
<TOT-CAPITALIZATION-AND-LIAB>                                 431,565
<GROSS-OPERATING-REVENUE>                                     84,058
<INCOME-TAX-EXPENSE>                                          3,227
<OTHER-OPERATING-EXPENSES>                                    46,077
<TOTAL-OPERATING-EXPENSES>                                    49,304
<OPERATING-INCOME-LOSS>                                       34,754
<OTHER-INCOME-NET>                                            1,193
<INCOME-BEFORE-INTEREST-EXPEN>                                35,947
<TOTAL-INTEREST-EXPENSE>                                      30,094
<NET-INCOME>                                                  5,853
<PREFERRED-STOCK-DIVIDENDS>                                   0
<EARNINGS-AVAILABLE-FOR-COMM>                                 5,853
<COMMON-STOCK-DIVIDENDS>                                      0
<TOTAL-INTEREST-ON-BONDS>                                     0
<CASH-FLOW-OPERATIONS>                                        30,710
<EPS-PRIMARY>                                                 5,853
<EPS-DILUTED>                                                 5,853
        



</TABLE>
###### Editorial Note on Part 201

#### Editorial Note:

Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

#### § 201.18 Drugs; significance of control numbers.

The lot number on the label of a drug should be capable of yielding the complete manufacturing history of the package. An incorrect lot number may be regarded as causing the article to be misbranded.
§ 211.28 Personnel responsibilities. ( a ) Personnel engaged in the manufacture, processing, packing, or holding of a drug product shall wear clean clothing appropriate for the duties they perform. Protective apparel, such as head, face, hand, and arm coverings, shall be worn as necessary to protect drug products from contamination.
( b ) Personnel shall practice good sanitation and health habits.
( c ) Only personnel authorized by supervisory personnel shall enter those areas of the buildings and facilities designated as limited-access areas.
( d ) Any person shown at any time (either by medical examination or supervisory observation) to have an apparent illness or open lesions that may adversely affect the safety or quality of drug products shall be excluded from direct contact with components, drug product containers, closures, in-process materials, and drug products until the condition is corrected or determined by competent medical personnel not to jeopardize the safety or quality of drug products. All personnel shall be instructed to report to supervisory personnel any health conditions that may have an adverse effect on drug products.
§ 50.55 Requirements for permission by parents or guardians and for assent by children. ( a ) In addition to the determinations required under other applicable sections of this subpart D, the IRB must determine that adequate provisions are made for soliciting the assent of the children when in the judgment of the IRB the children are capable of providing assent.
( b ) In determining whether children are capable of providing assent, the IRB must take into account the ages, maturity, and psychological state of the children involved. This judgment may be made for all children to be involved in clinical investigations under a particular protocol, or for each child, as the IRB deems appropriate.
( c ) The assent of the children is not a necessary condition for proceeding with the clinical investigation if the IRB determines: ( 1 ) That the capability of some or all of the children is so limited that they cannot reasonably be consulted, or
( 2 ) That the intervention or procedure involved in the clinical investigation holds out a prospect of direct benefit that is important to the health or well-being of the children and is available only in the context of the clinical investigation.
( d ) Even where the IRB determines that the subjects are capable of assenting, the IRB may still waive the assent requirement if it finds and documents that: ( 1 ) The clinical investigation involves no more than minimal risk to the subjects;
( 2 ) The waiver will not adversely affect the rights and welfare of the subjects;
( 3 ) The clinical investigation could not practicably be carried out without the waiver; and
( 4 ) Whenever appropriate, the subjects will be provided with additional pertinent information after participation.
( e ) In addition to the determinations required under other applicable sections of this subpart D, the IRB must determine, in accordance with and to the extent that consent is required under part 50, that the permission of each child's parents or guardian is granted. ( 1 ) Where parental permission is to be obtained, the IRB may find that the permission of one parent is sufficient for clinical investigations to be conducted under § 50.51 or § 50.52.
( 2 ) Where clinical investigations are covered by § 50.53 or § 50.54 and permission is to be obtained from parents, both parents must give their permission unless one parent is deceased, unknown, incompetent, or not reasonably available, or when only one parent has legal responsibility for the care and custody of the child.
( f ) Permission by parents or guardians must be documented in accordance with and to the extent required by § 50.27.
( g ) When the IRB determines that assent is required, it must also determine whether and how assent must be documented.
[66 FR 20598, Apr. 24, 2001, as amended at 78 FR 12951, Feb. 26, 2013]
Editorial Note on Part 101
Editorial Note: Nomenclature changes to part 101 appear at 63 FR 14035, Mar. 24, 1998, 66 FR 17358, Mar. 30, 2001, 66 FR 56035, Nov. 6, 2001, and 81 FR 49895, July 29, 2016.

§ 101.43 Substantial compliance of food retailers with the guidelines for the voluntary nutrition labeling of raw fruit, vegetables, and fish. ( a ) The Food and Drug Administration (FDA) will judge a food retailer who sells raw agricultural commodities or raw fish to be in compliance with the guidelines in § 101.45 with respect to raw agricultural commodities if the retailer displays or provides nutrition labeling for at least 90 percent of the raw agricultural commodities listed in § 101.44 that it sells, and with respect to raw fish if the retailer displays or provides nutrition labeling for at least 90 percent of the types of raw fish listed in § 101.44 that it sells. To be in compliance, the nutrition labeling shall: ( 1 ) Be presented in the store or other type of establishment in a manner that is consistent with § 101.45(a)(1);
( 2 ) Be presented in content and format that are consistent with § 101.45 (a)(2), (a)(3), and (a)(4); and
( 3 ) Include data that have been provided by FDA in appendices C and D to part 101 of this chapter, except that the information on potassium is voluntary.
( b ) To determine whether there is substantial compliance by food retailers with the guidelines in § 101.45 for the voluntary nutrition labeling of raw fruit and vegetables and of raw fish, FDA will select a representative sample of 2,000 stores, allocated by store type and size, for raw fruit and vegetables and for raw fish.
( c ) FDA will find that there is substantial compliance with the guidelines in § 101.45 if it finds based on paragraph (a) of this section that at least 60 percent of all stores that are evaluated are in compliance.
( d ) FDA will evaluate substantial compliance separately for raw agricultural commodities and for raw fish.
[55 FR 60890, Nov. 27, 1991, as amended at 61 FR 42759, Aug. 16, 1996]
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 675 Introduced in House (IH)]

109th CONGRESS
  2d Session
H. RES. 675

 Expressing disapproval of the Arab League's decision to hold its 2006 
     summit in Khartoum, Sudan and calling on the Arab League, the 
Government of Sudan, the Sudanese rebels, and the world community to do 
  all they can to end acts of genocide in the Darfur region of Sudan.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 14, 2006

  Mr. Pallone (for himself, Mr. Tancredo, Mr. Payne, Mr. Lantos, Mr. 
Burton of Indiana, Ms. Lee, Mr. McCotter, Ms. Watson, Ms. Ros-Lehtinen, 
Mr. Delahunt, Mr. Rohrabacher, Ms. McCollum of Minnesota, Mr. Wilson of 
    South Carolina, Mr. Ackerman, Mr. Brown of Ohio, Mr. Engel, Mr. 
 Capuano, Mr. Wolf, Mr. Hastings of Florida, Ms. Jackson-Lee of Texas, 
Mr. Rangel, Mr. Holt, Mr. Wynn, Ms. Eddie Bernice Johnson of Texas, Mr. 
Doyle, Mr. Israel, Mr. Honda, Mr. McNulty, Mr. Evans, Mrs. Maloney, Mr. 
  Al Green of Texas, Mr. McGovern, Ms. Schakowsky, Ms. Bordallo, Mr. 
Nadler, Mr. Doggett, and Ms. Linda T. Sanchez of California) submitted 
   the following resolution; which was referred to the Committee on 
                        International Relations

_______________________________________________________________________

                               RESOLUTION

 
 Expressing disapproval of the Arab League's decision to hold its 2006 
     summit in Khartoum, Sudan and calling on the Arab League, the 
Government of Sudan, the Sudanese rebels, and the world community to do 
  all they can to end acts of genocide in the Darfur region of Sudan.

Whereas the Arab League has tentatively scheduled its 2006 summit to be held in 
        Khartoum, Sudan in March 2006;
Whereas the Government of Sudan continues to allow acts of genocide in the 
        Darfur region of Sudan and deliberately obstructs the ability of the 
        African Union (AU) to stabilize the Darfur region;
Whereas the decision to hold the 2006 Arab League summit in Sudan is an economic 
        reward for a country that is currently under United States sanctions and 
        should be under United Nations sanctions; and
Whereas the decision to hold the 2006 Arab League summit in Sudan will encourage 
        the Government of Sudan to continue to allow acts of genocide and other 
        mistreatment against the people of the Darfur region of Sudan: Now, 
        therefore, be it
    Resolved, That the House of Representatives--
            (1) disapproves of the Arab League's decision to hold its 
        2006 summit in Khartoum, Sudan; and
            (2) continues to call on the Arab League, the Government of 
        Sudan, the Sudanese rebels, and the world community to do all 
        they can to end the acts of genocide in the Darfur region of 
        Sudan.
                                 <all>
```
United States Court of Appeals 

for the Fifth Circuit 

No. 20-40032 

Conference Calendar 

United States of America, 

Plaintiff—Appellee, 

versus

Cesar Mendoza-Hernandez, 

Defendant—Appellant. 

Appeal from the United States District Court 

for the Southern District of Texas 

USDC No. 1:19-CR-625-1 

Before Graves, Willett, and Duncan, Circuit Judges. 

Per Curiam:*

The attorney appointed to represent Cesar Mendoza-Hernandez has 

moved for leave to withdraw and has filed a brief in accordance with Anders 

v. California, 386 U.S. 738 (1967), and United States v. Flores, 632 F.3d 229 

(5th Cir. 2011). Mendoza-Hernandez has filed a response. We have 

*

 Pursuant to 5th Circuit Rule 47.5, the court has determined that this 

opinion should not be published and is not precedent except under the limited 

circumstances set forth in 5th Circuit Rule 47.5.4. 

United States Court of Appeals 

Fifth Circuit 

FILED 

April 6, 2021 

Lyle W. Cayce 

Clerk 

Case: 20-40032 Document: 00515810745 Page: 1 Date Filed: 04/06/2021
No. 20-40032 

2 

reviewed counsel’s brief and the relevant portions of the record reflected 

therein, as well as Mendoza-Hernandez’s response. We concur with 

counsel’s assessment that the appeal presents no nonfrivolous issue for 

appellate review. Accordingly, counsel’s motion for leave to withdraw is 

GRANTED, counsel is excused from further responsibilities herein, and 

the appeal is DISMISSED. See 5th Cir. R. 42.2. 

Case: 20-40032 Document: 00515810745 Page: 2 Date Filed: 04/06/2021
[No. 15947-7-III.

Division Three.

December 23, 1997.]

#### The Gilbert H. Moen Co., *Appellant,*v. Spokane River Associates, et al., *Respondents.*

Appeal from a judgment of the Superior Court for Spokane County, No. 94-2-03613-5, Michael E. Donohue, J., entered June 28,1996. *Affirmed*by unpublished opinion per Schultheis, A.C.J., concurred in by Kurtz and Brown, JJ.
##### 



EXHIBIT 99.2

Certification of Chief Financial
Officer

Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Republic
Bancorp Inc. (the Company) hereby certifies, to such officers knowledge,
that the Companys Quarterly Report on Form 10-Q for the quarter ended
September 30, 2002 (the Report) fully complies with the requirements of
Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934
and the information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.

Dated: November 13, 2002

/s/ Thomas F. Menacher

Thomas F. Menacher, CPAExecutive Vice President, Treasurer
and Chief Executive Officer

The foregoing certification accompanies the filing and is being furnished
solely pursuant to 18 U.S.C. Section 1350.
##### 



Exhibit 32 (b)
 CERTIFICATION PURSUANT TO 18 U.S.CSECTION 1350, AS ADOPTED PURSUANT
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
  (1)
    
    The Form 10-Q fully complies with the requirements of Section 13 (a) or
(15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78(d)); and(2)
    
    The information contained in the Form 10-Q fairly presents in all
material respects, the financial condition and results of operations of the
Partnership.
 Date:
5-14-07
 /s/
    
    GARY S. JONES

Gary S. Jones
President
 A signed original of this written statement required by Section 906 has been provided to
Northland Cable Properties Seven Limited Partnership and will be retained by Northland Cable
Properties Seven Limited Partnership and furnished to the Securities and Exchange Commission or its
staff upon request.
Editorial Note on Part 316
Editorial Note: Nomenclature changes to part 316 appear at 69 FR 13717, Mar. 24, 2004.

§ 316.26 Amendment to orphan-drug designation. ( a ) At any time prior to approval of a marketing application for a designated orphan drug, the sponsor holding designation may apply for an amendment to the designated use if the proposed change is due to new and unexpected findings in research on the drug, information arising from FDA recommendations, or unforeseen developments in treatment or diagnosis of the disease or condition.
( b ) FDA will grant the amendment if it finds that the initial designation request was made in good faith and that the amendment is intended to conform the orphan-drug designation to the results of unanticipated research findings, to unforeseen developments in the treatment or diagnosis of the disease or condition, or to changes based on FDA recommendations, and that, as of the date of the submission of the amendment request, the amendment would not result in exceeding the prevalence or cost recovery thresholds in § 316.21(a)(1) or (a)(2) upon which the drug was originally designated.
[78 FR 35134, June 12, 2013]
§ 515.10 Medicated feed mill license applications. ( a ) Medicated feed mill license applications (Form FDA 3448) may be obtained from the Public Health Service, Consolidated Forms and Publications Distribution Center, Washington Commerce Center, 3222 Hubbard Rd., Landover, MD 20785, or electronically from the Center for Veterinary Medicine at: *https://www.fda.gov/animal-veterinary/animal-food-feeds/medicated-feeds .*
( b ) A completed medicated feed mill license must contain the following information: ( 1 ) The full business name and address of the facility at which the manufacturing is to take place.
( 2 ) The facility's FDA registration number as required by section 510 of the Federal Food, Drug, and Cosmetic Act (the act).
( 3 ) The name, title, and signature of the responsible individual or individuals for that facility.
( 4 ) A certification that the animal feeds bearing or containing new animal drugs are manufactured and labeled in accordance with the applicable regulations published under section 512(i) of the act or in accordance with the index listing published under section 572(e)(2) of the act.
( 5 ) A certification that the methods used in, and the facilities and controls used for, manufacturing, processing, packaging, and holding such animal feeds conform to current good manufacturing practice as described in section 501(a)(2)(B) of the act and in part 225 of this chapter.
( 6 ) A certification that the facility will establish and maintain all records required by regulation or order issued under sections 512(m)(5)(A) or 504(a)(3)(A) of the act, and will permit access to, or copying or verification of such records.
( 7 ) A commitment that current approved or index listed Type B and/or Type C medicated feed labeling for each Type B and/or Type C medicated feed to be manufactured will be in the possession of the feed manufacturing facility prior to receiving the Type A medicated article containing such drug.
( 8 ) A commitment to renew registration every year with FDA as required in part 207 of this chapter.
( c ) Applications must be completed, signed, and submitted to the Food and Drug Administration, Center for Veterinary Medicine, Division of Food Compliance, 12225 Wilkins Ave., Rockville, MD 20852, or email (via attachment): *MedicatedFeedsTeamMail@fda.hhs.gov .*
( d ) Applications that are facially deficient will be returned to the applicant. All reasons for the return of the application will be made known to the applicant.
( e ) Upon approval, the application will be signed by an authorized employee of FDA designated by the Commissioner of Food and Drugs, and a copy will be returned to the applicant.
[64 FR 63204, Nov. 19, 1999, as amended at 72 FR 69121, Dec. 6, 2007; 81 FR 60221, Aug. 31, 2016; 87 FR 58960, Sept. 29, 2022; 89 FR 51966, June 21, 2024]
§ 520.1156 Imidacloprid. ( a ) *Specifications.* Each chewable tablet contains 7.5 or 37.5 milligrams (mg) imidacloprid.
( b ) *Sponsor.* See No. 058198 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer daily one 7.5-mg chewable tablet to dogs weighing 4 to 22 pounds (lb) or one 37.5-mg chewable table to dogs weighing 23 to 110 lb.
( 2 ) *Indications for use.* Kills adult fleas and is indicated for the treatment of flea infestations on dogs and puppies 10 weeks of age and older and weighing 4 lb or greater.
( 3 ) *Limitations.* Do not give to puppies younger than 10 weeks of age or to dogs weighing less than 4 lb. Do not give more than one tablet a day.
[80 FR 18775, Apr. 8, 2015, as amended at 86 FR 14818, Mar. 19, 2021]